

## Biomarkers for the Progression from Psoriasis to Psoriatic Arthritis

Courtney Carroll<sup>1</sup>, Trilokraj Tejasvi<sup>2</sup>, Lam C. Tsoi<sup>2</sup>, Rajan P Nair<sup>2</sup>, David E. Goldgar<sup>1</sup>, Kristina Callis Duffin<sup>1</sup>, Ana-Maria Orbai<sup>3</sup>, Philip E. Stuart<sup>2</sup>, James T. Elder<sup>2,4</sup>, Gerald G. Krueger<sup>1</sup>, Jessica A. Walsh<sup>5</sup>, Bing-Jian Feng<sup>1\*</sup>

1. University of Utah Department of Dermatology, Salt Lake City, USA; 2. University of Michigan Department of Dermatology, Ann Arbor, USA;

3. Johns Hopkins University Arthritis Center, Baltimore, USA; 4. Ann Arbor VA Hospital, Ann Arbor, USA; 5. University of Utah Division of Rheumatology, Salt Lake City, USA; \* [bingjian.feng@hsc.utah.edu](mailto:bingjian.feng@hsc.utah.edu)

### Background

Early diagnosis of psoriatic arthritis (PsA) is important for psoriasis (PsO) patient management. Bloodborne protein biomarkers of early PsA would be optimal. However, few studies have identified biomarkers specific to the progression of cutaneous-only psoriasis (PsC) to PsA.

### Methods




Figure 1: The Utah Psoriasis Initiative (UPI).




Figure 2: Study design.

WES, whole-exome sequencing; QC, quality control; UPI, Utah Psoriasis Initiative; UM, University of Michigan. \* Converter: patients who initially enrolled as PsC and then subsequently diagnosed with PsA. PsC for proteomic analysis: PsC patients who had been followed for at least ten years without converting to PsA.

### Results

#### 1. Susceptibility genes and pathways identified through exome-wide Cox proportional hazards regression

- Association of *OSTF1* was genome-wide significant in the Utah cohort ( $p=0.000043$ ) and was confirmed in the Michigan cohort ( $p=0.040$ ). A gene set called "Positive Regulation of Osteoclast Differentiation" was associated in the Michigan ( $p=0.000031$ , multiple-testing corrected  $p$ -value  $P_c=0.00046$ ), further supporting the involvement of osteoclasts in the etiology of PsA.
- A gene set identified from the Utah cohort ( $p=0.000092$ ), Cobalamin Binding, was confirmed in the Michigan cohort ( $p=0.006$ ,  $P_c=0.041$ ).

#### 2. Biomarkers identified from protein candidates selected based on exome sequencing results

Table 1: Candidate selection

Criterion	Selected candidates assayed by SomaScan
Confirmed susceptibility gene	OSTF1 (osteoclast stimulating factor 1)
Nominally associated genes in confirmed susceptibility pathways	TCN1, CD320, CBLIF (Cobalamin Binding) GPR68 (Osteoclast Differentiation)
Secreted proteins correlated with the above	TRAP (an osteoclast marker encoded by the ACP5 gene) <sup>1</sup>




Figure 3: Association of plasma protein biomarkers with PsA.

In the Kaplan-Meier curves, blue is biomarker-low and red is biomarker-high separated by the median. Findings from these figures:

- OSTF1, TRAP, and TCN1 showed a significant corrected  $p$ -value.
- The direction of association was consistent across the following tests
  - Comparison of the mean concentration between PsC and converters
  - Testing for the linear trend of expression by time among converters
  - Cox regression comparing biomarker-low to biomarker-high patients
  - Cox regression comparing deleterious variant carriers to non-carriers

#### 3. Predictive value of the biomarkers

In a previous study, we found that two clinical phenotypes (untreated psoriasis plaque thickness and history of fingernail psoriasis) were significantly associated with the conversion of PsC to PsA.<sup>2</sup> In this study, logistic regression suggested that ACP5 and TCN1 had additional predictive value beyond these clinical phenotypes (Table 2).

Table 2: Predictive value of biomarkers beyond clinical predictors.

Biomarker	Adjusted for untreated PsO thickness and history of fingernail PsO			
	Adjusted for symptoms		Excluded patients with symptoms	
	OR [95% CI]	p-value	OR [95% PI]	p-value
TCN1	0.41 [0.21,0.82]	<b>0.011</b>	0.32 [0.13,0.78]	<b>0.012</b>
TRAP	2.19 [1.08,4.44]	<b>0.029</b>	2.99 [1.21,7.42]	<b>0.018</b>
OSTF1	0.57 [0.28,1.16]	0.12	0.38 [0.14,1.02]	0.055

Note: All analyses were adjusted for age, sex, body mass index. Symptoms were morning stiffness >30 minutes, swelling, tenderness, deformity, or dactylitis.

#### 4. Biomarker concentration as a function of time before PsA

Spline regression tests showed that OSTF1 was consistently low for up to 7.1 years before conversion to PsA, and TCN1 was consistently low for up to 8.9 years before conversion to PsA (Figure 4).




Figure 4: Scatter plots with spline regression model.

Time zero represents PsA conversion. The line represents output of a one-knot one-degree spline regression. Only biomarkers with a significant likelihood ratio test result comparing the best-fit spline regression to a linear regression model are shown in this figure. P-values from the likelihood ratio tests were 0.016 and 0.013 for OSTF1 and TCN1, respectively.

### Conclusion

This study identified *OSTF1* as a PsA susceptibility gene, Osteoclast Differentiation and Cobalamin Binding as susceptibility pathways, and plasma protein concentration of OSTF1, TRAP, and TCN1 as biomarkers of early PsA. Biomarkers TCN1 and TRAP provided predictive information beyond what can be learned from clinical phenotype data.

### Acknowledgements & Disclosures

Research at the University of Utah has been supported by the ASPIRE US Rheuma IBD Grant (WI227108 to B.-J.F. and J.A.W.) from Pfizer Inc., the Investigator Sponsored Research (ISR) grants (WI240276 and 66334819 to B.-J.F. and J.A.W.) from Pfizer Inc., the Utah Genome Project Partnership Grant (B.-J.F. and J.A.W.) and the Immunology, Inflammation, & Infectious Disease (3i) Initiative Seed Grant (B.-J.F. and J.A.W.) from the University of Utah. The whole-exome sequencing was sponsored and conducted by the Regeneron Genetics Center (RGC), New York, USA. The clinical predictor analysis was partially supported by the National Psoriasis Foundation. The computational resources at the Center for High-Performance Computing, University of Utah, were partially funded by the NIH Shared Instrumentation Grant 1S10OD021644-01A1.

Research at the University of Michigan has been supported by the National Psoriasis Foundation (J.T.E., L.C.T., and Z.Z.), awards from the National Institutes of Health (K01AR072129 to L.C.T.; P30AR075043 to J.T.E., L.C.T., and Z.Z.); R01AR042742, R01AR050511, R01AR054966, R01AR063611, and R01AR065183 to J.T.E.), and the Babcock Memorial Trust. J.T.E. is supported by the Ann Arbor VA Hospital.

The PERCH software, for which B.-J.F. is the inventor, has been non-exclusively licensed to Amby Genetics Corporation for their clinical genetic testing services and research. B.-J.F. also reports funding and sponsorship to his institution on his behalf from Pfizer Inc. and Regeneron Genetics Center LLC. L.C.T. has received support from Janssen and Galderma. The remaining authors declare no potential conflicts of interest relevant to this article.

### References

- Marton N, Kovács OT, Baricza E, Kittel Á, Györi D, Mócsai A, Meier FMP, Goodyear CS, McInnes IB, Buzás EI, Nagy G. Extracellular vesicles regulate the human osteoclastogenesis: divergent roles in discrete inflammatory arthropathies. *Cell Mol Life Sci.* 2017 Oct;74(19):3599-3611. PMID: 28493076.
- Belman S, Walsh JA, Carroll C, Milliken M, Haaland B, Duffin KC, Krueger GG, Feng BJ. Psoriasis Characteristics for the Early Detection of Psoriatic Arthritis. *J Rheumatol.* 2021 Oct;48(10):1559-1565. PMID: 33858798; PMCID: PMC8487898.